Panbela Therapeutics, Inc.
PBLA · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.00 | -0.00 | 1.68 |
| FCF Yield | -122.83% | -56.13% | -546.30% | -0.07% |
| EV / EBITDA | -1.19 | -0.97 | -0.79 | -676.53 |
| Quality | ||||
| ROIC | 121.71% | 127.13% | -654.57% | -1,451.11% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.30 | 0.14 | 1.32 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -116.11% | 89.55% | -204.94% | 53.87% |
| Safety | ||||
| Net Debt / EBITDA | -0.93 | -0.68 | -0.55 | -0.41 |
| Interest Coverage | -32.42 | -137.34 | -106.76 | -97.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -137.54 | -158.75 | -113.82 | -126.93 |